The Nature and Origin of Amyloid Fibrils Book

	Chairman's introduction	1
	In memoriam	4
	A molecular model of the amyloid fibril	6
	Refined fibril structures: the hydrophobic core in Alzheimer's amyloid [beta]-protein and prion as revealed by X-ray diffraction	22
	General discussion I: Fibril structure	40
	General discussion I: Amyloid fibril toxicity	44
	Modulating conformational factors in transthyretin amyloid	47
	Proteoglycans and amyloid fibrillogenesis	58
	Molecular mechanisms of fibrillogenesis and the protective role of amyloid P component: two possible avenues for therapy
	General discussion II: Human calcitonin fibrillogenesis	90
	General discussion II: Proteolysis of amyloidogenic proteins	97
	Metabolism of amyloid proteins	104
	Alzheimer's disease: genesis of amyloid	119
	Apolipoprotein E and amyloidogenesis	132
	Interaction of transthyretin with amyloid [beta]-protein: binding and inhibition of amyloid formation	146
	General discussion III: Apolipoprotein E, TTR and Alzheimer's disease	165
	[beta]-amyloid precursor protein and early-onset Alzheimer's disease	170
	Prion protein amyloid: separation of scrapie infectivity from PrP polymers	181
	General discussion IV: Cell free conversion of protease-sensitive prion protein to the protease-resistant state: requirement for aggregates of scrapie-associated prion protein	202
	Ageing and amyloid fibrillogenesis: lessons from apolipoprotein AI, transthyretin and islet amyloid polypeptide	205
	General discussion V: 4'-lodo-4'-deoxydoxorubicin for the treatment of AL amyloidosis	223
	FAP mutations destabilize transthyretin facilitating conformational changes required for amyloid formation	228
	Index of contributors	243
	Subject index	245